Bortezomib (Page 8 of 8)
Principal Display Panel
NDC 72266-243-01
BORTEZOMIB (bortezomib) INJECTION
3.5 mg per 3.5 mL
(1 mg per mL)
FOR INTRAVENOUS USE ONLY
READY-to-use Vial
SINGLE DOSE VIAL
DISCARD UNUSED PORTION
CAUTION: Hazardous Agent
Vial Label 3.5 mg/ 3.5 mL
Carton Label 3.5 mg/ 3.5 mL
NDC 72266-244-01
BORTEZOMIB (bortezomib) INJECTION
3.5 mg per 1.4 mL
(2.5 mg per mL)
FOR INTRAVENOUS USE ONLY
Ready-to-use Vial
CAUTION: Hazardous Agent
Vial Label 3.5 mg/ 1.4 mL
Carton Label 3.5 mg/ 1.4 mL
BORTEZOMIB bortezomib injection | ||||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
|
BORTEZOMIB bortezomib injection | ||||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
|
Labeler — FOSUN PHARMA USA INC (080920998) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Gland Pharma Limited | 918601238 | manufacture (72266-243), manufacture (72266-244) |
Revised: 08/2022 FOSUN PHARMA USA INC
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.